Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Dr. Reddy's Laboratories Limited (RDY)

NYSE - Nasdaq Real Time Price. Currency in USD
54.66+0.18 (+0.33%)
At close: 01:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close54.48
Open54.52
Bid54.57 x 800
Ask54.61 x 900
Day's Range54.45 - 54.93
52 Week Range47.88 - 65.86
Volume108,890
Avg. Volume237,626
Market Cap9.075B
Beta (5Y Monthly)0.22
PE Ratio (TTM)23.87
EPS (TTM)2.29
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 08, 2021
1y Target Est62.37
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
20% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for RDY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Dr. Reddy's Laboratories Ltd
    Analyst Report: Dr. Reddy's Laboratories LimitedHeadquartered in India, Dr. Reddy’s Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company’s sales are well dispersed across North America, India, and other emerging markets.
    Rating
    Fair Value
    Economic Moat
    25 days agoMorningstar
View more
Advertisement
Advertisement